Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RB1 negative |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HDAC Inhibitor |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04555837 | Phase Ib/II | Alisertib + Pembrolizumab | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | Completed | USA | 0 |
| NCT02933736 | Phase I | Ribociclib | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | Active, not recruiting | USA | 0 |
| NCT06498648 | Phase Ib/II | Abemaciclib + Gemcitabine Docetaxel + Gemcitabine | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | Suspended | USA | 0 |
| NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |